ASCO20: Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
Posted: Monday, June 22, 2020
According to a randomized, phase III trial, presented during the ASCO20 Virtual Scientific Program (Abstract 6001), secondary cytoreductive surgery in selected patients with recurrent ovarian cancer may improve progression-free survival. Rongyu Zang MD, PhD, of Fudan University, Shanghai, and collaborators from other Chinese hospitalsreported that this surgery may ultimately offer a long-term survival benefit, based on their interim analysis of accumulated treatment-free survival.
A total of 357 patients with a primary relapse of ovarian cancer who had at least a 6-month platinum-free interval were randomly assigned for the study. Patients underwent either secondary cytoreductive surgery followed by chemotherapy or chemotherapy alone. Primary study endpoints were progression-free and overall survival. A secondary endpoint was accumulated treatment-free survival, defined as the time of surgery and chemotherapy subtracted from the overall survival time.
The 60-day mortality rate in both groups was 0%. The median progression-free survival was 17.4 months with secondary cytoreductive surgery and chemotherapy versus 11.9 months with chemotherapy alone (hazard ratio = 0.58; 95% confidence interval = 0.45–0.74; P < .001). The median accumulated treatment-free survival was unreached with surgery; 39.5 months was observed with chemotherapy alone (hazard ratio = 0.59; 95% confidence interval = 0.38–0.91). Patients who had surgery were found to have a better accumulated treatment-free survival than those who did not, with a restricted mean survival time of 60 to 72 months and 6.2 months to 4.2 months, respectively. Both overall survival and accumulated treatment-free survival data were not yet mature.
Disclosure: The authors reported no conflicts of interest.
